During the past decade, Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 9 clinical trials were completed, i.e. on average, 28.1% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 9 clinical trials were completed. i.e. 32.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica" #1 sponsor was "Eli Lilly and Company" with 15 trials, followed by "Janssen Research & Development, LLC" with 11 trials sponsored, "Merck Sharp & Dohme LLC" with 3 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored and "Nektar Therapeutics" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "BeiGene, Ltd." with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica" are "Prostatic Neoplasms" (5 trials), "Type 2 Diabetes Mellitus" (4 trials), "Breast Neoplasms" (3 trials), "Neoplasm Metastasis" (3 trials) and "Type 2 Diabetes" (2 trials). Many other conditions were trialed in "Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica" in a lesser frequency.

Most popular intervention types in "Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica" are "Drug" (31 trials), "Biological" (5 trials), "Device" (1 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Insulin Degludec" (5 trials), "Pembrolizumab" (4 trials), "Prednisone" (4 trials) and "Tirzepatide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica" are 24 trials for "All" genders and 9 trials for "Male" genders.

Currently, there are NaN active trials in "Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica". undefined are not yet recruiting, 15 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".